학술논문
Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial
Document Type
Article
Author
Wang, Michael L ; Jain, Preetesh; Zhao, Shuangtao; Lee, Hun Ju; Nastoupil, Loretta; Fayad, Luis; Ok, Chi Young; Kanagal-Shamanna, Rashmi; Hill, Holly A; Yao, Yixin; Hagemeister, Fredrick B; Westin, Jason R; Fowler, Nathan; Samaniego, Felipe; Steiner, Raphael; Nair, Ranjit; Iyer, Swaminathan P; Navsaria, Lucy; Badillo, Maria; Feng, Lei; Xuelin, Huang; Nogueras Gonzalez, Graciela M; Xu, Guofan; Wagner-Bartak, Nicolaus; Thirumurthi, Selvi; Santos, David; Tang, Guilin; Lin, Pei; Wang, Sa A; Jorgensen, Jeff; Yin, C Cameron; Li, Shaoying; Patel, Keyur P; Vega, Francisco; Medeiros, L Jeffery; Flowers, Christopher R; Wang, Linghua
Source
In The Lancet Oncology March 2022 23(3):406-415
Subject
Language
ISSN
1470-2045